$AEON ISIN: US00791X2099 Forum: Aktien User: 00000

⏰ Positive analytical biosimilarity data and an upcoming FDA Type 2a meeting materially de‑risk the regulatory path in the near term. AEON presents an analytical package showing ABP-450 matches BOTOX® at the amino‑acid level and demonstrates highly similar functional characteristics; LC‑MS showed a 100% sequence match for the primary structure with 93–99% coverage across the five proteins of the 900 kDa complex, which directly addresses a core technical requirement for biosimilarity. Regulatory progress now depends on the FDA’s interpretation at the November 19, 2025 Type 2a meeting and on whether the submitted analytical data suffice to limit or avoid larger clinical comparability studies; the meeting outcome will materially shape required next steps and timelines. - Stocktitan-